Drug Profile
KDU 731
Alternative Names: ABO-809; EDI-048; KDU-731Latest Information Update: 23 Jan 2023
Price :
$50
*
At a glance
- Originator Novartis; University of Georgia; Washington State University
- Developer Novartis
- Class Antiparasitics; Pyrazolones; Pyridines; Small molecules
- Mechanism of Action 1-phosphatidylinositol 4-kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cryptosporidiosis
Most Recent Events
- 27 Dec 2022 Novartis completes a phase I trial in Cryptosporidiosis (In volunteers) in USA (PO) (NCT05036668)
- 25 Apr 2022 Phase-I clinical trials in Cryptosporidiosis (In volunteers) in United Kingdom (PO) (ISRCTN38693215)
- 06 Apr 2022 Phase-I clinical trials in Cryptosporidiosis (In volunteers) in USA (PO) (NCT05036668)